Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects.
about
Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanilPharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions.CYP3A activity: towards dose adaptation to the individual.Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.
P2860
Q34810573-52CBEC5E-83D9-4A71-AF3B-17D355CD5C35Q35725540-504F6EB8-53BC-4A04-8742-4C163C3BBC06Q35781985-1D08F045-EF06-4BD3-9FEA-71AE5A00C436Q36469701-927D2D6F-B134-4508-9367-101429361803Q36578060-4F914FBE-C9A5-4A57-9795-9E347653ED9CQ36646017-96939C89-5D0A-421D-994D-2F2F11BA246DQ36922212-3731B716-E5D7-472E-8320-750E019B12D3Q37135750-58C71F17-ADAB-422C-82C2-A6F924EC0D8BQ38763583-FE422A20-34B1-4ECE-81CE-EA52E9C384FAQ46107342-090FFB04-5BB9-4D3A-8042-2DF2D7A36200Q46908040-66DB60D9-9B07-4B34-BA4B-17F7609AC52AQ48228997-2B1B87C3-38DB-40D5-8876-502DB9386398
P2860
Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Single plasma concentrations o ...... clearance in healthy subjects.
@en
Single plasma concentrations o ...... clearance in healthy subjects.
@nl
type
label
Single plasma concentrations o ...... clearance in healthy subjects.
@en
Single plasma concentrations o ...... clearance in healthy subjects.
@nl
prefLabel
Single plasma concentrations o ...... clearance in healthy subjects.
@en
Single plasma concentrations o ...... clearance in healthy subjects.
@nl
P2093
P1476
Single plasma concentrations o ...... clearance in healthy subjects.
@en
P2093
Angela D M Kashuba
Anne N Nafziger
Daniel S Streetman
Edna F Choo
Grant R Wilkinson
Janyce F Rogers
Joseph S Bertino
Mario L Rocci
P304
P356
10.1177/009127002401382614
P577
2002-10-01T00:00:00Z